NDAINTRAVENOUSSOLUTION
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
XIFYRM (meloxicam) by R-Pharm US is cyclooxygenase inhibitors [moa]. Approved for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis. First approved in 2025.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XIFYRM (meloxicam) is an intravenous nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain. It is indicated for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The IV formulation offers an alternative delivery route to oral meloxicam for patients requiring systemic anti-inflammatory therapy.
Launch15.2 years to LOE
Early-stage launch with zero identified competitive pressure; small commercial infrastructure likely required initially with growth dependent on clinical adoption and payer coverage.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications (3)
Worked on XIFYRM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.